^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

APOBEC3B (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3B)

i
Other names: APOBEC3B, Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3B, PHRBNL, Apolipoprotein B MRNA Editing Enzyme, Catalytic Polypeptide-Like 3B, DNA DC->DU-Editing Enzyme APOBEC-3B, Phorbolin-1-Related Protein, Phorbolin-2/3, Phorbolin 3, FLJ21201, A3B, Probable DNA DC->DU-Editing Enzyme APOBEC-3b, Cytidine Deaminase, Phorbolin 2, DJ742C19, BK150C2.2, APOBEC1L, ARCD3, ARP4
5d
R-loop editing by DNA cytosine deaminase APOBEC3B modulates the activity of oestrogen receptor enhancers. (PubMed, Nat Commun)
Furthermore, BER-mediated processing of A3B-induced uracil bases contributes to the formation of R-loop-associated DSBs, which are essential for ER-regulated gene activation. These findings establish a role for A3B in R-loop homeostasis and transcriptional regulation, with implications for understanding ER-driven genomic instability and potential therapeutic targeting of A3B.
Journal
|
ER (Estrogen receptor) • APOBEC3B (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3B)
11d
Differential effects on tumor progression by APOBEC3A, APOBEC3B, and APOBEC3H Haplotype I in a breast cancer mouse xenograft model. (PubMed, Front Genet)
Consistent with tumor data, RNA-seq showed upregulation of tumor enhancing pathways only in cells that enhanced tumor progression. The results indicate that in a breast cancer xenograft model, APOBEC3A and APOBEC3H Haplotype I are more likely to contribute to enhanced tumor progression than APOBEC3B.
Preclinical • Journal
|
APOBEC3B (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3B) • APOBEC3A (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3A) • APOBEC3H (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3H)
12d
Mus musculus papillomavirus MmuPV1 resists restriction by human APOBEC3B. (PubMed, J Virol)
Surprisingly, we find that human A3B is incapable of blocking the replication of a murine papillomavirus (Mus musculus papillomavirus 1, MmuPV1) in relevant primary cells from these animals or in infected tissues in vivo. These findings highlight the complexity of teasing apart host-pathogen interactions and suggest that papillomaviruses may have a general mechanism for escaping restriction by antiviral enzymes, such as A3B.
Journal
|
APOBEC3B (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3B)
14d
Insertional activity of human Alu and L1 retrotransposons is associated with DNA repair pathways and genome instability in cancer. (PubMed, Comput Biol Med)
Finally, the signature was associated with worse overall survival in pancreatic cancer (HR 5.9) and lesser effects in stomach, lung, and cervical cancers. These results shed light on the interplay of TE activities, DNA repair, and genome instability in human cancers.
Journal • Tumor mutational burden
|
TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • APOBEC3B (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3B)
25d
Integrated metabolome and transcriptome analysis reveals ferroptosis involvement in cisplatin resistance of esophageal squamous cancer cell. (PubMed, Comput Struct Biotechnol J)
These findings indicate the critical role of ferroptosis and glutathione metabolism in the development and progression of ESCC. Meanwhile, APOBEC3B may serve as a promising therapeutic target for cisplatin-resistant ESCC cells.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • APOBEC3B (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3B)
|
cisplatin
26d
HPV, APOBEC3B, and the origins of breast cancer: a narrative review and perspectives on novel mechanisms. (PubMed, Front Oncol)
The synthesized evidence suggests that high-risk HPV types are present in a subset of breast cancers worldwide, but with lower viral loads compared to cervical cancer, indicating a potentially different mode of action. The association between HPV and breast cancer warrants further rigorous investigation to clarify its clinical and preventive implications.
Review • Journal
|
APOBEC3B (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3B)
28d
APOBEC3B/ASF1B-TGF-β signaling axis promotes epithelial-mesenchymal transition in HPV-positive oropharyngeal cancer. (PubMed, J Dent Sci)
Silencing APOBEC3B reduced RPA2 and ASF1B levels and suppressed TGF-β signaling. These findings identify APOBEC3B/ASF1B as a central pathway through which HPV infection activates TGF-β signaling and promotes EMT, offering potential biomarkers and therapeutic targets for high-risk HPV-positive OPC.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1) • APOBEC3B (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3B) • APOB (Apolipoprotein B) • ASF1B (Anti-Silencing Function 1B Histone Chaperone) • RPA2 (Replication Protein A2)
2ms
APOBEC3B-driven mutations negatively regulated by P53 promote tumor progression and immunosuppressive microenvironment in prostate cancer. (PubMed, Mol Cell Biochem)
This infiltration may be mediated by cytokines and chemokines. Collectively, these findings suggest that A3B holds potential as a novel prognostic biomarker and immunotherapeutic target for PCa.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD163 (CD163 Molecule) • APOBEC3B (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3B)
|
TP53 mutation
3ms
Mus Musculus papillomavirus MmuPV1 resists restriction by human APOBEC3B. (PubMed, bioRxiv)
Surprisingly, we find that human A3B is incapable of blocking the replication of a murine papillomavirus ( Mus musculus papillomavirus 1, MmuPV1) in relevant primary cells from these animals or in infected tissues in vivo . These findings highlight the complexity of teasing apart host-pathogen interactions and suggest that papillomaviruses may have a general mechanism for escaping restriction by antiviral enzymes such as A3B.
Journal
|
APOBEC3B (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3B)